Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tiago Reis

Showing results (91-100 of 134) with videos related to

Pageof 14
Sort By:
JAMA Psychiatry|December 10, 2025
Role of Serotonin in the Neurobiology of Schizophrenia and Association With Negative SymptomsMartin Osugo, Thomas Whitehurst, David Erritzoe, et al.
Brain, Behavior, and Immunity|April 25, 2026
Peripheral inflammation is associated with reduced influx of TSPO PET tracers into the brain: insights from a non-invasive mapping methodologyLeonardo Barzon, Lucia Maccioni, Manuela Moretto, et al.
Schizophrenia Research|July 30, 2017
Utilising symptom dimensions with diagnostic categories improves prediction of time to first remission in first-episode psychosisOlesya Ajnakina, John Lally, Marta Di Forti, et al.
Schizophrenia Research|September 16, 2009
Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: the role of stress and of antipsychotic treatmentValeria Mondelli, Paola Dazzan, Nilay Hepgul, et al.
Nature Communications|January 16, 2020
Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in ratsEllis Chika Onwordi, Els F Halff, Thomas Whitehurst, et al.
Translational Psychiatry|March 2, 2025
The relationship between cortical synaptic terminal density marker SV2A and glutamate early in the course of schizophrenia: a multimodal PET and MRS imaging studyEllis Chika Onwordi, Thomas Whitehurst, Ekaterina Shatalina, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|February 2, 2026
Whole brain grey matter synaptic terminal density, age and intellectual functioning in schizophrenia: an in vivo [<sup>11</sup>C]UCB-J positron emission tomography studyEllis Chika Onwordi, Thomas Whitehurst, Ekaterina Shatalina, et al.
Biological Psychiatry|July 27, 2012
Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis usersMarta Di Forti, Conrad Iyegbe, Hannah Sallis, et al.
The British Journal of Psychiatry : the Journal of Mental Science|April 19, 2022
Real-world clinical and cost-effectiveness of community clozapine initiation: mirror cohort studyEmma Butler, Toby Pillinger, Kirsten Brown, et al.
Psychiatry Research|July 7, 2015
Association between the COMT gene and neurological abnormalities and poorer executive function in psychosisSarah Tosato, Elisa Ira, Manuela Russo, et al.
Pageof 14

Showing results (91-100 of 134) with videos related to

Sort By:
Pageof 14
JAMA Psychiatry|December 10, 2025
Role of Serotonin in the Neurobiology of Schizophrenia and Association With Negative SymptomsMartin Osugo, Thomas Whitehurst, David Erritzoe, et al.
Brain, Behavior, and Immunity|April 25, 2026
Peripheral inflammation is associated with reduced influx of TSPO PET tracers into the brain: insights from a non-invasive mapping methodologyLeonardo Barzon, Lucia Maccioni, Manuela Moretto, et al.
Schizophrenia Research|July 30, 2017
Utilising symptom dimensions with diagnostic categories improves prediction of time to first remission in first-episode psychosisOlesya Ajnakina, John Lally, Marta Di Forti, et al.
Schizophrenia Research|September 16, 2009
Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: the role of stress and of antipsychotic treatmentValeria Mondelli, Paola Dazzan, Nilay Hepgul, et al.
Nature Communications|January 16, 2020
Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in ratsEllis Chika Onwordi, Els F Halff, Thomas Whitehurst, et al.
Translational Psychiatry|March 2, 2025
The relationship between cortical synaptic terminal density marker SV2A and glutamate early in the course of schizophrenia: a multimodal PET and MRS imaging studyEllis Chika Onwordi, Thomas Whitehurst, Ekaterina Shatalina, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|February 2, 2026
Whole brain grey matter synaptic terminal density, age and intellectual functioning in schizophrenia: an in vivo [<sup>11</sup>C]UCB-J positron emission tomography studyEllis Chika Onwordi, Thomas Whitehurst, Ekaterina Shatalina, et al.
Biological Psychiatry|July 27, 2012
Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis usersMarta Di Forti, Conrad Iyegbe, Hannah Sallis, et al.
The British Journal of Psychiatry : the Journal of Mental Science|April 19, 2022
Real-world clinical and cost-effectiveness of community clozapine initiation: mirror cohort studyEmma Butler, Toby Pillinger, Kirsten Brown, et al.
Psychiatry Research|July 7, 2015
Association between the COMT gene and neurological abnormalities and poorer executive function in psychosisSarah Tosato, Elisa Ira, Manuela Russo, et al.
Pageof 14